Disease · MONDO_0006512
estrogen-receptor positive breast cancer
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. estrogen-receptor positive breast cancer. Diseases, record MONDO_0006512. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006512
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs35
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LETROZOLE | CHEMBL1444 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| TAMOXIFEN | CHEMBL83 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PALBOCICLIB | CHEMBL189963 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VEPDEGESTRANT | CHEMBL5095210 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FULVESTRANT | CHEMBL1358 | Small molecule | Phase 2 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| ANASTROZOLE | CHEMBL1399 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| AMCENESTRANT | CHEMBL4475463 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 35
See all 35 drugsTargets104
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ESR1 | Estrogen receptor | 7 | Estrogen receptor agonist; Estrogen receptor alpha antagonist; Estrogen receptor alpha degrader; Estrogen receptor alpha modulator; Estrogen receptor degrader; Estrogen receptor modulator | Phase 3 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| CYP19A1 | Aromatase | 3 | Cytochrome P450 19A1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1588 | Drugs and targets |
| GNRHR | Gonadotropin-releasing hormone receptor | 3 | Gonadotropin-releasing hormone receptor agonist | Phase 2 | https://conductscience.org/library/genes/2798 | Drugs and targets |
| AR | Androgen receptor | 2 | Androgen Receptor antagonist | Phase 2 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CDK4 | Cyclin-dependent kinase 4 | 2 | Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor | Phase 3 | https://conductscience.org/library/genes/1019 | Drugs and targets |
| CDK6 | CDK6/cyclin D1 | 2 | CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 6 inhibitor | Phase 3 | https://conductscience.org/library/genes/1021 | Drugs and targets |
| ESR2 | Estrogen receptor | 2 | Estrogen receptor agonist; Estrogen receptor modulator | Phase 2 | https://conductscience.org/library/genes/2100 | Drugs and targets |
| ABL1 | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor | Unknown | https://conductscience.org/library/genes/25 | Drugs and targets |
| ALK | ALK tyrosine kinase receptor | 1 | ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | Phase 2 | https://conductscience.org/library/genes/238 | Drugs and targets |
| BCR | Bcr/Abl fusion protein | 1 | Bcr/Abl fusion protein inhibitor | Unknown | https://conductscience.org/library/genes/613 | Drugs and targets |
1 to 10 of 104
See all 104 targetsTrials29
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01509625 | Retrospective Study Assessment Treatment Response Faslodex®( 500 mg) | 272 | 2016-06-01 | Malignant Neoplasm of Breast Stage IV | FULVESTRANT | Its record names the disease | ClinicalTrials.gov | |
| NCT01587703 | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Phase 1 | 196 | 2020-03-16 | Carcinoma, Midline | MOLIBRESIB | Its record names the disease | ClinicalTrials.gov |
| NCT03284957 | Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer | Phase 1/2 | 136 | 2025-11-24 | Breast Cancer | ABEMACICLIB, ALPELISIB, AMCENESTRANT, EVEROLIMUS, PALBOCICLIB | Its record names the disease | ClinicalTrials.gov |
| NCT00259090 | Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer | Phase 2 | 120 | 2012-08-16 | Breast Cancer | ANASTROZOLE, FULVESTRANT | Its record names the disease | ClinicalTrials.gov |
| NCT04191382 | Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer | Phase 2 | 105 | 2022-06-29 | Breast Cancer | AMCENESTRANT, LETROZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02993159 | Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast | Phase 2 | 100 | 2024-12-18 | Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive | AFIMOXIFENE, TAMOXIFEN CITRATE | Its record names the disease | ClinicalTrials.gov |
| NCT05659563 | Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% | Phase 2 | 92 | 2026-03-19 | Breast Cancer, Breast Cancer, Early-Onset | GIREDESTRANT, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT02311933 | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | Phase 2 | 81 | 2021-09-28 | Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7 | ENDOXIFEN, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT02392611 | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | Phase 1 | 33 | 2020-12-29 | Solid Tumors and Lymphomas | ALOBRESIB, EXEMESTANE, FULVESTRANT | Its record names the disease | ClinicalTrials.gov |
| NCT03620643 | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours | Phase 2 | 33 | 2025-10-30 | Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation | CRIZOTINIB, FULVESTRANT | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 29
See all 29 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm I (4-OHT Topical Gel, Placebo) vs Arm II (Placebo, Oral Tamoxifen): deaths from any cause | 0 of 47 | 0 of 53 | 100 | NCT02993159 | Trial comparisons |
| Arm I (4-OHT Topical Gel, Placebo) vs Arm II (Placebo, Oral Tamoxifen): serious adverse events | 0 of 47 | 0 of 53 | 100 | NCT02993159 | Trial comparisons |
| Arm A vs Arm B: deaths from any cause | 0 of 42 | 0 of 44 | 86 | NCT05659563 | Trial comparisons |
| Arm A vs Arm B: serious adverse events | 0 of 42 | 0 of 44 | 86 | NCT05659563 | Trial comparisons |
| Arm I (Z-endoxifen Hydrochloride) vs Arm II (Tamoxifen Citrate): deaths from any cause | 1 of 41 | 0 of 39 | 80 | NCT02311933 | Trial comparisons |
| Arm I (Z-endoxifen Hydrochloride) vs Arm II (Tamoxifen Citrate): serious adverse events | 8 of 41 | 11 of 39 | 80 | NCT02311933 | Trial comparisons |
| Crizotinib Oral Capsule [Xalkori] Monotherapy vs Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection: Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) | 6 of 6 | 27 of 27 | 33 | NCT03620643 | Trial comparisons |
| Crizotinib Oral Capsule [Xalkori] Monotherapy vs Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection: deaths from any cause | 6 of 6 | 20 of 27 | 33 | NCT03620643 | Trial comparisons |
| Crizotinib Oral Capsule [Xalkori] Monotherapy vs Crizotinib Oral Capsule [Xalkori] Plus Fulvestrant Injection: serious adverse events | 4 of 6 | 5 of 27 | 33 | NCT03620643 | Trial comparisons |
| 80mg Amor+6mg Iso/80mg Bes+6mg Iso/30mg Bes+6mg Iso/80mg Bes vs 80mg Bes+6mg Iso/80mg Amor+6mg Iso/30mg Bes+6mg Iso/80mg Bes: Number of Participants With PSA50 Response-Besylate Sub-study | 0 of 5 | 0 of 5 | 10 | NCT01587703 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials20
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006512
GET https://conductscience.org/api/diseases/v1/MONDO_0006512/drugs?page=2